NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Up 42.7% in February

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 230,100 shares, an increase of 42.7% from the January 31st total of 161,300 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily volume of 273,600 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC raised its holdings in NeuroSense Therapeutics by 640.9% in the 4th quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock valued at $305,000 after acquiring an additional 219,717 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics during the fourth quarter valued at approximately $78,000. Finally, XTX Topco Ltd raised its stake in shares of NeuroSense Therapeutics by 40.9% in the third quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock valued at $58,000 after purchasing an additional 13,346 shares in the last quarter. Institutional investors own 1.04% of the company’s stock.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 16th.

NeuroSense Therapeutics Trading Up 4.8 %

NRSN opened at $1.10 on Wednesday. The business has a 50 day moving average of $1.13 and a 200-day moving average of $1.12. The stock has a market capitalization of $15.03 million, a price-to-earnings ratio of -1.72 and a beta of 1.27. NeuroSense Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.25.

NeuroSense Therapeutics (NASDAQ:NRSN) last issued its quarterly earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.